Esperion Therapeutics, Inc.
ESPR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $412 | $308 | $414 | $145 |
| - Cash | $145 | $82 | $125 | $209 |
| + Debt | $591 | $541 | $261 | $260 |
| Enterprise Value | $858 | $767 | $550 | $196 |
| Revenue | $332 | $116 | $75 | $78 |
| % Growth | 185.7% | 54.1% | -3.8% | – |
| Gross Profit | $264 | $73 | $49 | $64 |
| % Margin | 79.4% | 62.8% | 64.3% | 81.9% |
| EBITDA | $8 | -$150 | -$176 | -$222 |
| % Margin | 2.3% | -129% | -233.7% | -283.2% |
| Net Income | -$52 | -$209 | -$234 | -$269 |
| % Margin | -15.6% | -179.9% | -309.6% | -343% |
| EPS Diluted | -0.28 | -2.03 | -4.33 | -11.03 |
| % Growth | 86.2% | 53.1% | 60.7% | – |
| Operating Cash Flow | -$24 | -$135 | -$175 | -$264 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$24 | -$135 | -$175 | -$264 |